{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:21:29Z","timestamp":1770888089737,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,1,18]],"date-time":"2017-01-18T00:00:00Z","timestamp":1484697600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s00277-017-2920-2","type":"journal-article","created":{"date-parts":[[2017,1,18]],"date-time":"2017-01-18T05:39:17Z","timestamp":1484717957000},"page":"639-646","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12\u00a0years follow-up of a phase 2 trial"],"prefix":"10.1007","volume":"96","author":[{"given":"Laura","family":"Magnano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Montoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Gonz\u00e1lez-Barca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Briones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Manuel","family":"Sancho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Munta\u00f1ola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Salar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Besalduch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lourdes","family":"Escoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Domingo-Domenech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Estany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Alt\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Pedro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Gardella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoni","family":"Asensio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Vivancos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Fern\u00e1ndez de Sevilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep Mar\u00eda","family":"Ribera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolors","family":"Colomer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Campo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"L\u00f3pez-Guillermo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,18]]},"reference":[{"issue":"Suppl 1","key":"2920_CR1","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1038\/sj.thj.6200388","volume":"5","author":"M Hallek","year":"2004","unstructured":"Hallek M, Eichhorst BF (2004) Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia. Hematol J 5(Suppl 1):S20\u2013S30","journal-title":"Hematol J"},{"key":"2920_CR2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","volume":"25","author":"IW Flinn","year":"2007","unstructured":"Flinn IW, Neuberg DS, Grever MR et al (2007) Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US intergroup trial E2997. J Clin Oncol 25:793\u2013798","journal-title":"J Clin Oncol"},{"key":"2920_CR3","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1200\/JCO.2005.02.172","volume":"23","author":"MS Czuczman","year":"2005","unstructured":"Czuczman MS, Koryzna A, Mohr A et al (2005) Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 23:694\u2013704","journal-title":"J Clin Oncol"},{"key":"2920_CR4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/ejh.12384","volume":"93","author":"VF De la Cruz","year":"2014","unstructured":"De la Cruz VF, Carrillo-Cruz E, Rodriguez MS et al (2014) Fludarabine, cyclophosphamide and rituximab as first-line treatment in patients with newly diagnosed follicular lymphoma. Eur J Haematol 93:469\u2013475","journal-title":"Eur J Haematol"},{"key":"2920_CR5","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1080\/10428190310001623874","volume":"45","author":"G Santini","year":"2004","unstructured":"Santini G, Chisesi T, Nati S et al (2004) Fludarabine, cyclophosphamide and mitoxantrone for untreated follicular lymphoma: a report from the non-Hodgkin\u2019s lymphoma co-operative study group. Leuk Lymphoma 45:1141\u20131147","journal-title":"Leuk Lymphoma"},{"key":"2920_CR6","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1200\/JCO.1994.12.3.575","volume":"12","author":"P McLaughlin","year":"1994","unstructured":"McLaughlin P, Hagemeister FB, Swan F et al (1994) Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol 12:575\u2013579","journal-title":"J Clin Oncol"},{"key":"2920_CR7","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1200\/JCO.1996.14.4.1262","volume":"14","author":"P McLaughlin","year":"1996","unstructured":"McLaughlin P, Hagemeister FB, Romaguera JE et al (1996) Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol 14:1262\u20131268","journal-title":"J Clin Oncol"},{"key":"2920_CR8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3324\/haematol.11671","volume":"93","author":"S Montoto","year":"2008","unstructured":"Montoto S, Moreno C, Domingo-Dom\u00e9nech E et al (2008) High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. Haematologica 93:207\u2013214","journal-title":"Haematologica"},{"key":"2920_CR9","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","volume":"31","author":"M Federico","year":"2013","unstructured":"Federico M, Luminari S, Dondi A et al (2013) R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol 31:1506\u20131513","journal-title":"J Clin Oncol"},{"key":"2920_CR10","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3324\/haematol.12120","volume":"93","author":"S Sacchi","year":"2008","unstructured":"Sacchi S, Marcheselli L, Bari A et al (2008) Secondary malignancies after treatment for indolent non-Hodgkin\u2019s lymphoma: a 16-year follow-up study. Haematologica 93:398\u2013404","journal-title":"Haematologica"},{"key":"2920_CR11","first-page":"1546","volume":"91","author":"CS Tam","year":"2006","unstructured":"Tam CS, Seymour JF, Prince HM et al (2006) Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica 91:1546\u20131550","journal-title":"Haematologica"},{"key":"2920_CR12","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1200\/JCO.2002.08.128","volume":"20","author":"VA Morrison","year":"2002","unstructured":"Morrison VA, Rai KR, Peterson BL et al (2002) Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol 20:3878\u20133884","journal-title":"J Clin Oncol"},{"key":"2920_CR13","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1182\/blood-2004-08-3035","volume":"105","author":"P McLaughlin","year":"2005","unstructured":"McLaughlin P, Estey E, Glassman A et al (2005) Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood 105:4573\u20134575","journal-title":"Blood"},{"key":"2920_CR14","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1038\/leu.2010.218","volume":"24","author":"DA Carney","year":"2010","unstructured":"Carney DA, Westerman DA, Tam CS et al (2010) Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia 24:2056\u20132062","journal-title":"Leukemia"},{"key":"2920_CR15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/modpathol.2011.158","volume":"25","author":"Y Zhou","year":"2012","unstructured":"Zhou Y, Tang G, Medeiros LJ et al (2012) Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma. Mod Pathol 25:237\u2013245","journal-title":"Mod Pathol"},{"key":"2920_CR16","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/annonc\/mdq697","volume":"22","author":"M Pirani","year":"2011","unstructured":"Pirani M, Marcheselli R, Marcheselli L et al (2011) Risk for second malignancies in non-Hodgkin\u2019s lymphoma survivors: a meta-analysis. Ann Oncol 22:1845\u20131858","journal-title":"Ann Oncol"},{"key":"2920_CR17","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.3109\/10428194.2012.743657","volume":"54","author":"Y Xu","year":"2013","unstructured":"Xu Y, Wang H, Zhou S et al (2013) Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma. Leuk Lymphoma 54:1396\u20131404","journal-title":"Leuk Lymphoma"},{"key":"2920_CR18","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244","journal-title":"J Clin Oncol"},{"key":"2920_CR19","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1182\/blood.V78.12.3275.3275","volume":"78","author":"JG Gribben","year":"1991","unstructured":"Gribben JG, Freedman AS, Woo SD et al (1991) All advanced stage non-Hodgkin\u2019s lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 78:3275\u20133280","journal-title":"Blood"},{"key":"2920_CR20","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/modpathol.3880116","volume":"13","author":"OC Estalilla","year":"2000","unstructured":"Estalilla OC, Medeiros LJ, Manning JT, Luthra R (2000) 5\u2032-->3\u2032 exonuclease-based real-time PCR assays for detecting the t(14;18)(q32;21): a survey of 162 malignant lymphomas and reactive specimens. Mod Pathol 13:661\u2013666","journal-title":"Mod Pathol"},{"key":"2920_CR21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/01621459.1974.10480131","volume":"69","author":"NBD Mantel","year":"1974","unstructured":"Mantel NBD (1974) Evaluation of response-time data involving transient states: an illustration using heart-transplant data. J Am Stat Assoc 69:81\u201386","journal-title":"J Am Stat Assoc"},{"key":"2920_CR22","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.2000.18.5.987","volume":"18","author":"HS Hochster","year":"2000","unstructured":"Hochster HS, Oken MM, Winter JN et al (2000) Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and long-term follow-up\u2014a report from the Eastern Cooperative Oncology Group. J Clin Oncol 18:987\u2013994","journal-title":"J Clin Oncol"},{"key":"2920_CR23","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3109\/10428194.2014.953144","volume":"56","author":"LJ Nastoupil","year":"2015","unstructured":"Nastoupil LJ, Sinha R, Byrtek M et al (2015) Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States. Leuk Lymphoma 56:1295\u20131302","journal-title":"Leuk Lymphoma"},{"key":"2920_CR24","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2004.07.170","volume":"22","author":"PL Zinzani","year":"2004","unstructured":"Zinzani PL, Pulsoni A, Perrotti A et al (2004) Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 22:2654\u20132661","journal-title":"J Clin Oncol"},{"key":"2920_CR25","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1182\/blood-2001-12-0269","volume":"100","author":"AM Tsimberidou","year":"2002","unstructured":"Tsimberidou AM, McLaughlin P, Younes A et al (2002) Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma. Blood 100:4351\u20134357","journal-title":"Blood"},{"key":"2920_CR26","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-14-0407","volume":"20","author":"S Galimberti","year":"2014","unstructured":"Galimberti S, Luminari S, Ciabatti E et al (2014) Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. Clin Cancer Res 20:6398\u20136405","journal-title":"Clin Cancer Res"},{"key":"2920_CR27","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood.V91.8.2955.2955_2955_2960","volume":"91","author":"A L\u00f3pez-Guillermo","year":"1998","unstructured":"L\u00f3pez-Guillermo A, Cabanillas F, McLaughlin P et al (1998) The clinical significance of molecular response in indolent follicular lymphomas. Blood 91:2955\u20132960","journal-title":"Blood"},{"issue":"Suppl 1","key":"2920_CR28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/11.suppl_1.S137","volume":"11","author":"A L\u00f3pez-Guillermo","year":"2000","unstructured":"L\u00f3pez-Guillermo A, Cabanillas F, McLaughlin P et al (2000) Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series. Ann Oncol 11(Suppl 1):137\u2013140","journal-title":"Ann Oncol"},{"key":"2920_CR29","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2000.18.3.527","volume":"18","author":"J Apostolidis","year":"2000","unstructured":"Apostolidis J, Gupta RK, Grenzelias D et al (2000) High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 18:527\u2013536","journal-title":"J Clin Oncol"},{"key":"2920_CR30","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1080\/10428190500467834","volume":"47","author":"L Arcaini","year":"2006","unstructured":"Arcaini L, Colombo N, Bernasconi P et al (2006) Role of the molecular staging and response in the management of follicular lymphoma patients. Leuk Lymphoma 47:1018\u20131022","journal-title":"Leuk Lymphoma"},{"key":"2920_CR31","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/blood-2013-06-507319","volume":"122","author":"M Ladetto","year":"2013","unstructured":"Ladetto M, Lobetti-Bodoni C, Mantoan B et al (2013) Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. Blood 122:3759\u20133766","journal-title":"Blood"},{"key":"2920_CR32","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1182\/blood-2004-06-2490","volume":"105","author":"A Rambaldi","year":"2005","unstructured":"Rambaldi A, Carlotti E, Oldani E et al (2005) Quantitative PCR of bone marrow BCL2\/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma. Blood 105:3428\u20133433","journal-title":"Blood"},{"key":"2920_CR33","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s12185-014-1629-4","volume":"100","author":"Y Hirayama","year":"2014","unstructured":"Hirayama Y, Ishitani K, Ota S et al (2014) Long-term survey of survival time, histological transformation, and secondary malignancies in Japanese patients with advanced-stage follicular lymphoma in the rituximab era: Hokkaido Hematology Study Group. Int J Hematol 100:281\u2013289","journal-title":"Int J Hematol"},{"key":"2920_CR34","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/bjc.2013.381","volume":"109","author":"S Beiggi","year":"2013","unstructured":"Beiggi S, Johnston JB, Seftel MD et al (2013) Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study. Br J Cancer 109:1287\u20131290","journal-title":"Br J Cancer"},{"key":"2920_CR35","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/jnci\/94.3.182","volume":"94","author":"LB Travis","year":"2002","unstructured":"Travis LB, Gospodarowicz M, Curtis RE et al (2002) Lung cancer following chemotherapy and radiotherapy for Hodgkin\u2019s disease. J Natl Cancer Inst 94:182\u2013192","journal-title":"J Natl Cancer Inst"},{"key":"2920_CR36","first-page":"1481","volume":"91","author":"EC Moser","year":"2006","unstructured":"Moser EC, Noordijk EM, van Leeuwen FE et al (2006) Risk of second cancer after treatment of aggressive non-Hodgkin\u2019s lymphoma; an EORTC cohort study. Haematologica 91:1481\u20131488","journal-title":"Haematologica"},{"key":"2920_CR37","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2007.14.6068","volume":"26","author":"K Hemminki","year":"2008","unstructured":"Hemminki K, Lenner P, Sundquist J, Bermejo JL (2008) Risk of subsequent solid tumors after non-Hodgkin\u2019s lymphoma: effect of diagnostic age and time since diagnosis. J Clin Oncol 26:1850\u20131857","journal-title":"J Clin Oncol"},{"key":"2920_CR38","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V92.4.1165","volume":"92","author":"MJ Keating","year":"1998","unstructured":"Keating MJ, O\u2019Brien S, Lerner S et al (1998) Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92:1165\u20131171","journal-title":"Blood"},{"key":"2920_CR39","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/annonc\/mds433","volume":"24","author":"P Bains","year":"2013","unstructured":"Bains P, Al Tourah A, Campbell BA et al (2013) Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy. Ann Oncol 24:428\u2013432","journal-title":"Ann Oncol"},{"key":"2920_CR40","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1365-2141.2012.09054.x","volume":"157","author":"A Conconi","year":"2012","unstructured":"Conconi A, Ponzio C, Lobetti-Bodoni C et al (2012) Incidence, risk factors and outcome of histological transformation in follicular lymphoma. Br J Haematol 157:188\u2013196","journal-title":"Br J Haematol"},{"key":"2920_CR41","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdl162","volume":"17","author":"E Gin\u00e9","year":"2006","unstructured":"Gin\u00e9 E, Montoto S, Bosch F et al (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Ann Oncol 17:1539\u20131545","journal-title":"Ann Oncol"},{"key":"2920_CR42","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","volume":"126","author":"ND Wagner-Johnston","year":"2015","unstructured":"Wagner-Johnston ND, Link BK, Byrtek M et al (2015) Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood 126:851\u2013857","journal-title":"Blood"},{"key":"2920_CR43","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","volume":"25","author":"S Montoto","year":"2007","unstructured":"Montoto S, Davies AJ, Matthews J et al (2007) Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 25:2426\u20132433","journal-title":"J Clin Oncol"},{"key":"2920_CR44","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3109\/10428194.2012.710327","volume":"54","author":"M Solh","year":"2013","unstructured":"Solh M, Rai KR, Peterson BL et al (2013) The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011). Leuk Lymphoma 54:252\u2013254","journal-title":"Leuk Lymphoma"},{"key":"2920_CR45","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A et al (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417\u20131423","journal-title":"Blood"},{"key":"2920_CR46","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F et al (2011) Rituximab maintenance for 2\u00a0years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377:42\u201351","journal-title":"Lancet"},{"key":"2920_CR47","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203\u20131210","journal-title":"Lancet"},{"key":"2920_CR48","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL et al (2015) Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol 33:2516\u20132522","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-2920-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-017-2920-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-2920-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T03:26:22Z","timestamp":1601349982000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-017-2920-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,18]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["2920"],"URL":"https:\/\/doi.org\/10.1007\/s00277-017-2920-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,18]]}}}